NCT06194500

A Study of Carbon-14-Labeled [14C]-LY3549492 in Healthy Participants

An Open-label, Two-part Study of the Disposition and Absolute Bioavailability of [14C]-LY3549492 in Healthy Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: Male
• Age: 35 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to measure how much of the study drug gets into the bloodstream and how long it takes the body to get rid of it. This study will be conducted in healthy males and has two parts. In Part A, participants will receive carbon-14 (14C) radiolabeled LY3549492 (\[14C\] LY3549492) given by mouth. In Part B, participants will receive LY3549492 by mouth. Three hours later, participants will receive \[14C\] LY3549492 given into a vein. The radioactive substance C14 will be incorporated into the study drug to investigate the study drug and breakdown products to find out how much of these passes from blood into urine, stool, and breath. The study will last about 2 months in Part A and about 1½ months in Part B. This includes screening, treatment, and follow-up visits.

Conditions

• Healthy Male

Interventions

Type	Name	Description
DRUG	[14C]-LY3549492	Administered as oral solution.
DRUG	LY3549492	Administered orally.
DRUG	[14C]-LY3549492	Administered as IV infusion.

Timeline

• Start date: 2024-01-03
• Primary completion: 2024-02-15
• Completion: 2024-02-15
• First posted: 2024-01-08
• Last updated: 2024-03-28

Locations

1 site across 1 country: United Kingdom